Designing the next generation of medicines for malaria control and eradication
详细信息 查看全文
- 作者：Jeremy N Burrows (4)
Rob Hooft van Huijsduijnen (4)
J?rg J M?hrle (4)
Claude Oeuvray (4)
Timothy NC Wells (4) - 关键词：Malaria ; Plasmodium ; Anopheles ; Drug discovery ; Medicines ; Target candidate profile ; Target product profile ; MMV
- 刊名：Malaria Journal
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：12
- 期：1
- 全文大小：871KB
- 参考文献：1. World Health Organization: / World Malaria Report. 2011. http://www.who.int/malaria/world_malaria_report_2011/en/
2. Roll Back Malaria: / RBM Anual Report 2011. 2012. http://www.rollbackmalaria.org/
3. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, / et al.: Genome sequence of the human malaria parasite Plasmodium falciparum . / Nature 2002, 419:498-11. CrossRef
4. Pain A, Bohme U, Berry AE, Mungall K, Finn RD, Jackson AP, Mourier T, Mistry J, Pasini EM, Aslett MA, Balasubrammaniam S, Borgwardt K, Brooks K, Carret C, Carver TJ, Cherevach I, Chillingworth T, Clark TG, Galinski MR, Hall N, Harper D, Harris D, Hauser H, Ivens A, Janssen CS, Keane T, Larke N, Lapp S, Marti M, Moule S, / et al.: The genome of the simian and human malaria parasite Plasmodium knowlesi . / Nature 2008, 455:799-03. CrossRef
5. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J, Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C, Gilson PR, Gueye AH, Guo X, Kang’a S, Kooij TW, Korsinczky M, Meyer EV, Nene V, Paulsen I, White O, Ralph SA, Ren Q, Sargeant TJ, / et al.: Comparative genomics of the neglected human malaria parasite Plasmodium vivax . / Nature 2008, 455:757-63. CrossRef
6. Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL: First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. / Br J Clin Pharmacol 2012, 75:524-37.
7. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL: Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. / Proc Natl Acad Sci USA 2011, 108:4400-405. CrossRef
8. van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M, van Gemert GJ, Rottmann M, Yeung BK, Diagana TT, Sauerwein RW: The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. / Antimicrob Agents Chemother 2012, 56:3544-548. CrossRef
9. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L: Artemisinin resistance: current status and scenarios for containment. / Nat Rev Microbiol 2010, 8:272-80. CrossRef
10. Yeung S, Socheat D, Moorthy VS, Mills AJ: Artemisinin resistance on the Thai-Cambodian border. / Lancet 2009, 374:1418-419. CrossRef
11. Sa JM, Chong JL, Wellems TE: Malaria drug resistance: new observations and developments. / Essays Biochem 2011, 51:137-60.
12. Griffin JB, Lokomba V, Landis SH, Thorp JM Jr, Herring AH, Tshefu AK, Rogerson SJ, Meshnick SR: Plasmodium falciparum parasitaemia in the first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: a longitudinal Doppler ultrasound study. / Malar J 2012, 11:319. CrossRef
13. The RTS, S Clinical Trials Partnership: A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. / N Engl J Med 2012, 367:2284-295. CrossRef
14. Barclay VC, Sim D, Chan BH, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF: The evolutionary consequences of blood-stage vaccination on the rodent malaria plasmodium chabaudi . / PLoS Biol 2012, 10:e1001368. CrossRef
15. Moiroux N, Gomez MB, Pennetier C, Elanga E, Djenontin A, Chandre F, Djegbe I, Guis H, Corbel V: Changes in anopheles funestus biting behavior following universal coverage of long-lasting insecticidal nets in benin. / J Infect Dis 2012, 206:1622-629. CrossRef
16. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D’Alessandro U: Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. / Malar J 2011, 10:50. CrossRef
17. Anthony MP, Burrows JN, Duparc S, Moehrle J, Wells TN: The global pipeline of new medicines for the control and elimination of malaria. / Malar J 2012, 11:316. CrossRef
18. The MMV Websitehttp://www.mmv.org
19. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: drugs. / PLoS Med 2011, 8:e1000402. CrossRef
20. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: health systems and operational research. / PLoS Med 2011, 8:e1000397. CrossRef
21. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: vector control. / PLoS Med 2011, 8:e1000401. CrossRef
22. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: vaccines. / PLoS Med 2011, 8:e1000398. CrossRef
23. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: basic science and enabling technologies. / PLoS Med 2011, 8:e1000399. CrossRef
24. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: diagnoses and diagnostics. / PLoS Med 2011, 8:e1000396. CrossRef
25. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: monitoring, evaluation, and surveillance. / PLoS Med 2011, 8:e1000400. CrossRef
26. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M: A research agenda to underpin malaria eradication. / PLoS Med 2011, 8:e1000406. CrossRef
27. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: modeling. / PLoS Med 2011, 8:e1000403. CrossRef
28. malERA Consultative Group on Vaccines: A research agenda for malaria eradication: cross-cutting issues for eradication. / PLoS Med 2011, 8:e1000404. CrossRef
29. Sanz LM, Crespo B, De-Cozar C, Ding XC, Llergo JL, Burrows JN, Garcia-Bustos JF, Gamo FJ: P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. / PLoS One 2012, 7:e30949. CrossRef
30. Rinaki E, Valsami G, Macheras P: Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. / Pharm Res 2003, 20:1917-925. CrossRef
31. Bruce MC, Day KP: Cross-species regulation of malaria parasitaemia in the human host. / Curr Opin Microbiol 2002, 5:431-37. CrossRef
32. Cox-Singh J, Singh B: Knowlesi malaria: newly emergent and of public health importance? / Trends Parasitol 2008, 24:406-10. CrossRef
33. Ding XC, Beck HP, Raso G: Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. / Trends Parasitol 2011, 27:73-1. CrossRef
34. Angulo-Barturen I, Jimenez-Diaz MB, Mulet T, Rullas J, Herreros E, Ferrer S, Jimenez E, Mendoza A, Regadera J, Rosenthal PJ, Bathurst I, Pompliano DL, Gomez de las Heras F, Gargallo-Viola D: A murine model of falciparum -malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. / PLoS One 2008, 3:e2252. CrossRef
35. Novartis Coartem package leaflethttp://www.coartem.com/downloads/IPL-Coartem.pdf
36. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BH, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukrittayakamee S: An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. / PLoS One 2010, 5:e11880. CrossRef
37. Stepniewska K, White NJ: Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. / Anti Microb Agents Chemother 2008, 52:1589-596. CrossRef
38. Lanners HN: Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum . / Parasitol Res 1991, 77:478-81. CrossRef
39. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S: High-dose primaquine regimens against relapse of Plasmodium vivax malaria. / Am J Trop Med Hyg 2008, 78:736-40.
40. Fernando D, Rodrigo C, Rajapakse S: Primaquine in vivax malaria: an update and review on management issues. / Malar J 2011, 10:351. CrossRef
41. Burrows JN, Leroy D, Lotharius J, Waterson D: Challenges in antimalarial drug discovery. / Future Med Chem 2011, 3:1401-412. CrossRef
42. Burrows JN, Chibale K, Wells TN: The state of the art in anti-malarial drug discovery and development. / Curr Top Med Chem 2011, 11:1226-254. CrossRef
43. Dembele L, Gego A, Zeeman AM, Franetich JF, Silvie O, Rametti A, Le Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ, Vaillant JC, Thomas AW, Snounou G, Kocken CH, Mazier D: Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. / PLoS One 2011, 6:e18162. CrossRef
44. Puri SK, Dutta GP: Causal prophylactic activity of a new 8-aminoquinoline derivative against Plasmodium cynomolgi B in rhesus monkeys. / Indian J Med Res 1990, 91:197-99.
45. Puri SK, Dutta GP: Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. / Acta Trop 2003, 86:35-0. CrossRef
46. Schmidt LH: Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys. / Anti Microb Agents Chemother 1983, 24:615-52. CrossRef
47. Jimenez-Diaz MB, Mulet T, Viera S, Gomez V, Garuti H, Ibanez J, Alvarez-Doval A, Shultz LD, Martinez A, Gargallo-Viola D, Angulo-Barturen I: Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. / Anti Microb Agents Chemother 2009, 53:4533-536. CrossRef
48. Baird JK, Fryauff DJ, Hoffman SL: Primaquine for prevention of malaria in travelers. / Clin Infect Dis 2003, 37:1659-667. CrossRef
49. van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM, Sauerwein RW: Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. / Parasitology 2005, 130:13-2. CrossRef
50. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, Bonnet S, Diallo M, Coulibaly M, Tchuinkam T, Mulder B, Targett G, Drakeley C, Sutherland C, Robert V, Doumbo O, Toure Y, Graves PM, Roeffen W, Sauerwein R, Birkett A, Locke E, Morin M, Wu Y, Churcher TS: Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. / PLoS One 2012, 7:e42821. CrossRef
51. Kern SE, Tiono AB, Makanga M, Gbadoe AD, Premji Z, Gaye O, Sagara I, Ubben D, Cousin M, Oladiran F, Sander O, Ogutu B: Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis. / Malar J 2011, 10:210. CrossRef
52. World Health Organization: / Updated WHO Policy Recommendation (October 2012). 2012. http://www.who.int/malaria/pq_updated_policy_recommendation_en_102012.pdf
53. Hems WP, Jackson WP, Nightingale P, Bryant R: Practical Asymmetric Synthesis of (+)-erythro Mefloquine Hydrochloride. / Org Process Res Dev 2012, 16:461-63. CrossRef
54. Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, Boutros MS, Rhein HG, Adamcova M: Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. / Clin Infect Dis 2012, 54:e124-e131. CrossRef
55. Jackson KE, Pham JS, Kwek M, De Silva NS, Allen SM, Goodman CD, McFadden GI, de Pouplana LR, Ralph SA: Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum . / Int J Parasitol 2012, 42:177-86. CrossRef
56. Fasan PO: Field trial of cycloguanil pamoate in the treatment and suppression of malaria in Nigerian school children: a preliminary report. / Trans R Soc Trop Med Hyg 1970, 64:839-49. CrossRef
57. McGregor IA, Williams K, Walker GH, Rahman AK: Cycloguanil pamoate in the treatment and suppression of malaria in the Gambia, West Africa. / Br Med J 1966, 1:695-01. CrossRef
58. Smithuis F, van der Broek I, Katterman N, Kyaw MK, Brockman A, Lwin S, White NJ: Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. / Trans R Soc Trop Med Hyg 2004, 98:182-92. CrossRef
59. Ogutu B, Tiono AB, Makanga M, Premji Z, Gbadoe AD, Ubben D, Marrast AC, Gaye O: Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? / Malar J 2010, 9:30. CrossRef
60. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, / et al.: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. / Lancet 2010, 376:1647-657. CrossRef
61. Dondorp A, Nosten F, Stepniewska K, Day N, White N: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. / Lancet 2005, 366:717-25. CrossRef
62. Craft JC: Drug Discovery for Lower Respiratory Tract Infections. In / Neglected Diseases and Drug Discovery. Edited by: Palmer MJ, Wells TNC. London, UK: Royal Society of Chemistry; 2011:366-11. CrossRef
63. Munos B: Lessons from 60 years of pharmaceutical innovation. / Nat Rev Drug Discov 2009, 8:959-68. CrossRef
64. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D: The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. / PLoS Med 2012, 9:e1001169. CrossRef - 作者单位：Jeremy N Burrows (4)
Rob Hooft van Huijsduijnen (4)
J?rg J M?hrle (4)
Claude Oeuvray (4)
Timothy NC Wells (4)
4. Medicines for Malaria Venture (MMV), PO Box 1826, route de Pré-Bois 20, Geneva, 15 1215, Switzerland
文摘
In the fight against malaria new medicines are an essential weapon. For the parts of the world where the current gold standard artemisinin combination therapies are active, significant improvements can still be made: for example combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or improved stability under field conditions. For those parts of the world where the existing combinations show less than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a secondary role. For new medicines to be optimal in malaria control they must also be able to reduce transmission and prevent relapse of dormant forms: additional constraints on a combination medicine. In the absence of a highly effective vaccine, new medicines are also needed to protect patient populations. In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested. In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles). MMV presents now a suggested framework for combining the new candidates to produce the new medicines. Sustained investment over the next decade in discovery and development of new molecules is essential to enable the long-term delivery of the medicines needed to combat malaria.